Members of the Switch Therapeutics team (L-R): Discovery biology director Lisa Scherer, CEO Dee Datta and chief technology officer Si-ping Han
Eli Lilly, UCB and others Switch into gear with $52M for new RNA biotech
South San Francisco biotech Switch Therapeutics unwrapped Tuesday morning with $52 million to finance conditionally activated siRNA molecules.
As its name suggests, the startup said it can switch on the molecules only in selected cells so they’re more precise than other RNAi approaches and can potentially be effective for longer periods. The biotech will start in the central nervous system and consider expanding its use in other disease areas through the help of potential pharma collaborators, CEO Dee Datta told Endpoints News.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters